Abstract 2222
Background
Naloxegol is a peripherally acting, µ-opioid receptor antagonist for treatment of opioid-induced constipation (OIC). The main objective of this study was to analyze the efficacy of naloxegol in patients with cancer in a real-world prospective study.
Methods
An observational, one year of follow-up study was conducted in 16 Spanish centers. Patients older than 18 years, with active oncological disease who were under treatment with opioids for pain control were selected. OIC with inadequate response to treatment with laxative (s) was the main diagnostic. The patients received treatment with naloxegol according to clinical criteria. Efficacy was assessed measuring the response rate and symptoms evolution measured by means of PAC-SYM questionnaire. Data of an intermediate analysis after 12 weeks of treatment are analyzed.
Results
A total of 126 patients were included in the study and 68 of them in this interim efficacy analysis. About 58.2% were men, with an average age of 61.3 years (34-89). Lung cancer was observed in 35.7%, breast cancer in 15.1% and 8,7% had prostate cancer. About 75.5% had metastases. Naloxegol at doses of 12.5 mg/day was administered to 14.7% and 25 mg/day to 85.3%. Concomitant laxatives were administered to 63.2% of the patients. At 12 weeks, 88.2% of the patients were responders to naloxegol treatment: 80% at doses of 12.5 mg/day, and 89.7% with 25 mg/day. Furthermore, 75% of patients without concomitant laxative treatment were responders with 12.5 mg/day dose of naloxegol and 90.5% were responders with 25 mg/day. A total of 24 adverse reactions appeared in 13.5% of the patients (17/126).
Conclusions
The results of this first real-world-data study in patients with cancer confirm the efficacy of naloxegol for the treatment of OIC in this group of patients. Naloxegol is safe and well tolerated in oncologic patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kyowa Kirin Farmacéutica, S.L.U. Madrid, Spain.
Funding
Kyowa Kirin Farmacéutica, S.L.U.
Disclosure
A.J. Jiménez López: Full / Part-time employment: Kyowa Kirin Farmacéutica, S.L.U.. I. Huerta González: Full / Part-time employment: Kyowa Kirin Farmacéutica, S.L.U. A. Sanz Yagüe: Full / Part-time employment: Kyowa Kirin Farmacéutica, S.L.U. B. Soler López: Advisory / Consultancy: Kyowa Kirin Farmacéutica, S.L.U. All other authors have declared no conflicts of interest.
Resources from the same session
5037 - CXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features
Presenter: Olga Savelieva
Session: Poster Display session 1
Resources:
Abstract
5729 - Expression of mutant p53 affects cancer cell sensitivity to topotecan
Presenter: Rimma Mingaleeva
Session: Poster Display session 1
Resources:
Abstract
5725 - Breast cancer organoids a new tool for the prediction of drugs penetration and patient’outcome
Presenter: Giuseppina Roscigno
Session: Poster Display session 1
Resources:
Abstract
5680 - Aptamer-mediated exosomes detection for early breast cancer identification.
Presenter: Cristina Quintavalle
Session: Poster Display session 1
Resources:
Abstract
2460 - MicroRNA-181c promotes tamoxifen resistance in breast cancer cells via upregulation Akt/mTOR axis
Presenter: Alexander Scherbakov
Session: Poster Display session 1
Resources:
Abstract
3751 - Spatio-temporal separation of tumor infiltrating CD8+ T-cells and HER2/neu+ tumor cells in tumor-immune milieu of infiltrating ductal carcinoma of the breast
Presenter: Sandhya Sreedharan
Session: Poster Display session 1
Resources:
Abstract
4664 - Large genomic rearrangements in BRCA1 and BRCA2 genes in the Portuguese population.
Presenter: Joao Pinto
Session: Poster Display session 1
Resources:
Abstract
4611 - Non-BRCA1/2 hereditary breast and ovarian cancer: findings from a multidisciplinary program
Presenter: Ana Monteiro
Session: Poster Display session 1
Resources:
Abstract
5340 - Quantitative imaging and characterization of collagen patterns in high grade serous ovarian carcinoma (HGSOC)
Presenter: Ruby Huang
Session: Poster Display session 1
Resources:
Abstract
4209 - Semiquantitative assessment of vimentin expression in prostate cancer (PC)
Presenter: Marina Puchinskaya
Session: Poster Display session 1
Resources:
Abstract